NORPACE CR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Norpace Cr, and when can generic versions of Norpace Cr launch?
Norpace Cr is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in NORPACE CR is disopyramide phosphate. There are nineteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the disopyramide phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Norpace Cr
A generic version of NORPACE CR was approved as disopyramide phosphate by TEVA on February 22nd, 1985.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NORPACE CR?
- What are the global sales for NORPACE CR?
- What is Average Wholesale Price for NORPACE CR?
Summary for NORPACE CR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 47 |
Clinical Trials: | 1 |
Patent Applications: | 1,138 |
Drug Prices: | Drug price information for NORPACE CR |
DailyMed Link: | NORPACE CR at DailyMed |
Recent Clinical Trials for NORPACE CR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Medtronic | Phase 3 |
Mayo Clinic | Phase 3 |
Pharmacology for NORPACE CR
Drug Class | Antiarrhythmic |
US Patents and Regulatory Information for NORPACE CR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | NORPACE CR | disopyramide phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 018655-001 | Jul 20, 1982 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pfizer | NORPACE CR | disopyramide phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 018655-002 | Jul 20, 1982 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |